Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Filings indexed 3,405 across all filing types
Latest filing 2026-05-27 Regulatory Filings
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
US FDA decision date on camizestrant extended
Regulatory Filings Classification · 90% confidence The text is a London Stock Exchange RNS announcement providing an update on the US FDA’s extension of the PDUFA date for AstraZeneca’s camizestrant filing. It contains no financial statements, no voting results, no share transactions, and no interim or annual report data. It is a generic regulatory announcement and falls under the fallback category for miscellaneous regulatory filings (RNS).
2026-05-27 English
US FDA DECISION DATE ON CAMIZESTRANT EXTENDED
Regulatory Filings
2026-05-27 English
DATROWAY APPROVED IN US FOR 1L TRIPLE-NEGATIVE BC
Regulatory Filings
2026-05-26 English
ENHERTU RECOMMENDED IN EU FOR HER2+ SOLID TUMOURS
Regulatory Filings
2026-05-26 English
CAMIZESTRANT RECOMMENDED FOR BREAST CANCER IN EU
Regulatory Filings
2026-05-26 English
Enhertu recommended in EU for HER2+ solid tumours
Regulatory Filings Classification · 90% confidence The document is an RNS press release announcing the CHMP recommendation for Enhertu approval. It is not a financial report, earnings release, or management call transcript, nor does it fit any specific category like M&A, dividends, or governance. It is a general regulatory announcement about a product approval in the EU, which falls under the fallback Regulatory Filings category.
2026-05-26 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.